Research Papers:

Circulating tumor cell is a common property of brain glioma and promotes the monitoring system

Faliang Gao, Yong Cui, Haihui Jiang, Dali Sui, Yonggang Wang, Zhongli Jiang, Jizong Zhao _ and Song Lin

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:71330-71340. https://doi.org/10.18632/oncotarget.11114

Metrics: PDF 2337 views  |   HTML 2953 views  |   ?  


Faliang Gao1,2,3, Yong Cui1,2,3, Haihui Jiang4, Dali Sui1,2,3, Yonggang Wang1,2,3, Zhongli Jiang1,2,3, Jizong Zhao1,2,3, Song Lin1,2,3

1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

2China National Clinical Research Center for Neurological Diseases, Beijing, China

3Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China

4Department of Neurosurgery, First Hospital of Tsinghua University, Beijing, China

Correspondence to:

Song Lin, email: [email protected]

Keywords: glioma, circulating tumor cell (CTC), biomarker, monitor, radionecrosis

Received: April 02, 2016    Accepted: July 10, 2016    Published: August 8, 2016


Brain glioma is the most common primary intracranial tumor characterized by dismal prognosis and frequent recurrence, yet a real-time and reliable biological approach to monitor tumor response and progression is still lacking. Recently, few studies have reported that circulating tumor cells (CTCs) could be detected in glioblastoma multiform (GBM), providing the possibility of its application in brain glioma monitoring system. But its application limits still exist, because the detection rate of CTCs is still low and was exclusively limited to high- grade gliomas. Here, we adopted an advanced integrated cellular and molecular approach of SE-iFISH to detect CTCs in the peripheral blood (PB) of patients with 7 different subtypes of brain glioma, uncovering the direct evidences of glioma migration. We identified CTCs in the PB from 24 of 31 (77%) patients with glioma in all 7 subtypes. No statistical difference of CTC incidence and count was observed in different pathological subtypes or WHO grades of glioma. Clinical data revealed that CTCs, to some extent, was superior to MRI in monitoring the treatment response and differentiating radionecrosis from recurrence of glioma. Conclusively, CTCs is a common property of brain gliomas of various pathological subtypes, which has provided an ultimate paradox for the hypothesis “soil and seed”. It can be used to monitor the microenvironment of gliomas dynamically, which will be a meaningful complement to radiographic imaging.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11114